Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma;Analýza sérových hladin vybraných biologických ukazatelů u monoklonální gamapatie nejistého významu a mnohočetného myelomu

Klinicka Onkologie

Volumn 23, Issue 3, 2010, Pages 171-181

  Ščudla, Vlastimil ^a   Budikova M ^a   Petrova P ^a   Minarik J ^a   Pika, T ^a   Bacovsky J ^a   Adamova D ^b   Langova K ^c  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b Hematologické a Transfuzní Odd lení Slezské Nemocnice   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Cytokines; Metabolism; Monoclonal gammopathy of undetermined significance; Multiple myeloma

Indexed keywords

ALKALINE PHOSPHATASE; ANGIOGENIN; BIOLOGICAL MARKER; ENDOSTATIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; INTERLEUKIN 17; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; SCATTER FACTOR; SOMATOMEDIN C; SYNDECAN 1; THYMIDINE KINASE; VASCULOTROPIN;

ARTICLE; BLOOD LEVEL; CHEMOLUMINESCENCE; CONTROLLED STUDY; ELECTROCHEMICAL ANALYSIS; ENZYME IMMUNOASSAY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; RADIOENZYMATIC ASSAY;

EID: 77954130939     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Hideshima T, Bergsagel PL, Kuehl MW et al. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104(3): 607-618. (Pubitemid 38970551)
2. Urashima M, Chen BP, Chen S et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997; 90(2): 754-765.
3. International Myeloma Working Group. Criteria for the clasification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121(5): 749-757.
4. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factor for progression. Brit J Haematol 2007; 139(5): 730-743.
5. Ščudla V, Budíková M, Pika T et al. Srovnání sérových hladin vybraných biologických ukazatelů u monoklonální gamapatie nejistého významu a mnohočetného myelomu. Vnitř Lék 2006; 52(3): 232-240.
6. Ščudla V, Budíková M, Pika T et al. Srovnání sérových hladin vybraných biologických působků u monoklonální gamapatie nejistého významu a mnohočetného myelomu. Čas Lék čes 2009; 148: 315-322.
7. Scudla V, Pika T, Budikova M et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma 2010; 57(2): 102-110.
8. Scudla V, Pika T, Budiková M et al. The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratifications systems. Biomed Pap Med 2009; 153(4): 275-282.
9. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36(3): 842-854.
10. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23(15): 3412-3420. (Pubitemid 46243484)
11. Hájek R, Adam Z, Maisnar V et al. Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou a Myelomovou sekcí České hematologické společnosti a Slovenskou myelómovou spoločností pro diagnostiku a léčbu mnohočetného myelomu. Transfuze Hematol dnes 2009; 15 (Suppl. 2): 1-80.
12. Bradwell AR. Serum free light chain analysis (plus Hevylite). 5th ed. Birmingham: The Binding Site Ltd 2008.
13. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134(6): 573-589.
14. Yacoby S, Pearse RN, Johnson CL et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116(2): 278-290.
15. Vacca A, Ria R, Ribatti D et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88(2): 176-185. (Pubitemid 37101495)
16. Pour L, Hájek R, Buchler T et al. Angiogeneze a antiangiogenní terapie u nádorů. Vnitř Lék 2004; 50(12): 930-938.
17. Holt RU, Fagerli UM, Baykov V et al. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 2008; 93(4): 619-622. (Pubitemid 351536394)
18. Seidel C, Børset M, Hjertner O et al High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000; 96(9): 3139-3146.
19. Heider U, Fleissner C, Zavrski I et al. Bone markers in multiple myeloma. Eur J Cancer 2006; 42(11): 1544-1553.
20. Fonseca R, Trendle MC, Leong T et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000; 109(1): 24-29. (Pubitemid 30340575)
21. Alexandrakis MG, Passam FH, Boula A et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003; 82(1): 19-23. (Pubitemid 36700965)
22. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: Focus on the receptor activator of NF-κB ligand (RANKL). Exp Hematol 2004; 32(8): 685-691. (Pubitemid 39092730)
23. Roux S, Meignin V, Quillard J et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002; 117(1): 86-92. (Pubitemid 34304425)
24. Abildgaard N, Bentzen SM, Nielsen JL, for the Nordic Myeloma Study Group (NMSG). Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haematol 1997; 96(1): 103-110.
25. Špička I, Cieslar P, Procházka B et al. Prognostické faktory a markery aktivity u mnohočetného myelomu. Čas Lék čes 2001; 139: 208-212.
26. Terpos E, Politou M, Szydlo R et al. Serum levels of macrophage inflammatory protein-1 a (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123(1): 106-109. (Pubitemid 37222765)
27. Abe M, Hiura K, Wilde J et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100(6): 2195-2202. (Pubitemid 35001256)
28. Choi SJ, Cruz JC, Craig F et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96(2): 671-675. (Pubitemid 30463390)
29. Graham GJ, Wright EG, Hewick R et al. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature 1990; 344(6265): 442-444. (Pubitemid 20110095)
30. Lentzsch S, Gries M, Janz M et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101(9): 3568-3573. (Pubitemid 36857943)
31. Hata H. Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1α) in human multiple myeloma. Leuk Lymphoma 2005; 46(7): 967-972. (Pubitemid 40975016)
32. Terpos E, Tasidou A, Roussou M et al. Increased expression of macrophage inflammatory protein-1 alpha on trephine biopsies correlates with advanced myeloma, extensive bone disease and elevated microvessel density in newly diagnosed patients with multiple myeloma. Haematologica 2009; 94 (Suppl 2): 146.
33. Hashimoto T, Abe M, Oshima T et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004; 125(1): 38-41. (Pubitemid 38453275)
34. Terpos E, Anagnostopoulos A, Kastritis E et al. The combination of bortezomib melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effectie regimen for relapsed/refractory myeloma and reduces serum levels of RANKL, MIP1A and angiogenic cytokines. Haematologica 2006; 91: 84.
35. Johnston NI, Gunasekharan VK, Ravindranath A et al. Osteopontin as a target for cancer therapy. Front Biosci 2008; 13: 4361-4372.
36. Lee CY, Tien HF, Hou HA et al. Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. Br J Haematol 2008; 141(5): 736-739.
37. Štifter S, Valković T, Načinović- Duletić A et al. Vascular endothelial growth factor, osteopontin and NF-κB/P65 expression in multiple myeloma. Haematologica 2008; 93 (Suppl. 1): 80.
38. Robbiani DF, Colon K, Ely S et al. Osteopontin dysregulation and lytic bone lesions in multiple myeloma. Hematol Oncol 2007; 25(1): 16-20. (Pubitemid 46474310)
39. Saeki Y, Mima T, Ishii T et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Brit J Haematol 2003; 123(2): 263-270.
40. Rajkumar SV, Mesa RA, Fonseca R et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8(7): 2210-2216. (Pubitemid 34753592)
41. Pour L, Svachova H, Adam Z et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010; 57(1): 29-33.
42. Pour L, Svachova H, Adam Z et al. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol 2009; 84(4): 332-336.
43. Sezer O, Jakob C, Eucker J et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66(2): 83-88. (Pubitemid 32154100)
44. Seidel C, Børset M, Turesson I et al, for the Nordic Myeloma Study Group. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 1998; 91(3): 806-812.
45. Hlavkova D, Kopecky O, Lukesova S et al. Monitoring of serum levels of angiogenin, ENA-78 ad GRO chemokines in patients with renal cell carcinoma (RCC) in the course of the treatment. Acta Medica 2008; 51(3): 185-190.
46. Passam FH, Sfiridaki A, Pappa C et al. Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Labor Hematol 2008; 30(1): 17-25.
47. Ergun S, Kilic N, Wurmback JH et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes Angiogenesis 2001; 4(3): 193-206. (Pubitemid 34174308)
48. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-285. (Pubitemid 28015876)
49. Dhodapkar MV, Kelly T, Theus A et al. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 1997; 99: 368-371. (Pubitemid 27497569)
50. Maisnar V, Toušková M, Malý J et al. Význam vybraných sledovaných laboratorních ukazatelů pro diferenciální diagnostiku a sledování aktivity mnohočetného myelomu. Vnitř Lék 2002; 48: 290-297.
51. Seidel C, Sundan A, Hjorth M et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000; 95(2): 388-392. (Pubitemid 30041645)
52. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in multiple myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 2004; 72(4): 252-258.
53. Schaar CG, Vermeer HJ, Wijermans PW et al. Serum syndecan-1 in patients with newly diagnosed monoclonal proteinaemia. Haematologica 2005; 90(10): 1437-1438.
54. Witzig TE, Kimlinger T, Stenson M et al. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998; 31(1-2): 167-175. (Pubitemid 28428760)
55. Tate JR, Gill D, Cobcroft R et al. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003; 49(8): 1252-1257. (Pubitemid 36900609)
56. Rajkumar VS. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Am Soc Hematol Educ Program 2005; 2005(1): 340-345.
57. Rajkumar SV, Kyle RA, Therneau TM et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106(3): 812-817.
58. Mead GP, Carr-Smith HD, Drayson MT et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126(3): 348-354.
59. Dispenzieri A, Zhang L, Katzmann J et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111(10): 4908-4915. (Pubitemid 351451470)
60. Corso A, Arcaini L, Mangiacavalli S et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 2001; 86(4): 394-398.
61. Renzulli MR, Terragna C, Testoni N et al. Insulin-like growth factor 1 (IGF-1) is overexpressed in multiple myeloma plasma cells (PC) and regulates the expression of the IGF-1 receptor. Haematologica 2006; 91: 87.
62. Menu E, van Valckenborhg E, van Camp B et al. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009; 115(2): 49-57.
63. Hsu JH, Shi Y, Krajewski S et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98(9): 2853-2855.
64. Greco C, Vitelli G, Vercillo G et al. Reduction of serum IGF-1 levels in patients affected with monoclonal gammopathies of undetermined significance or multiple myeloma. Comparison with bFGF, VEGF and κ-ras gene mutation. J Exp Clin Cancer Research 2009; 28: 35.
65. Seidel C, Hjertner Ø, Abildgaard N et al, for Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
66. Terpos E, Szydlo R, Apperley JF et al. Soluble receptor activator of nuclear factor κ-B ligand - osteoprotegerin ratio predicts survival in multiple myeloma proposal for a novel prognostic index. Blood 2003; 102(3): 1064-1069 (Pubitemid 36917805)
67. Corso A, Dovio A, Rusconi C et al. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age and sex-matched healthy controls. Leukemia 2004; 18(9): 1555-1557. (Pubitemid 39264084)
68. Dhodapkar KM, Barbuto S, Matthews P et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112(7): 2878-2885.